[1] ARTASENSI A,PEDRETTI A,VISTOLI G,et al.Type 2 diabetes mellitus:A review of multi-target drugs[J].Molecules,2020,25(8):1987. [2] AIBAR-ALMAZÁN A,VOLTES-MARTÍNEZ A,CASTELLOTE-CABALLERO Y,et al.Current status of the diagnosis and management of osteoporosis[J].Int J Mol Sci,2022,23(16):9465. [3] 杨利娇,张利平,贾小月,等.基于定量CT不同年龄患者腰椎骨质疏松的危险因素分析[J].中国临床医生杂志,2024,52(7):804-807. [4] WU B,FU Z,WANG X,et al.A narrative review of diabetic bone disease:Characteristics,pathogenesis,and treatment[J].Front Endocrinol(Lausanne),2022(13):1052592. [5] XIA Y,ZHANG H,WANG H,et al.Identification and validation of ferroptosis key genes in bone mesenchymal stromal cells of primary osteoporosis based on bioinformatics analysis[J].Front Endocrinol(Lausanne),2022(139):980867. [6] LAMOIA T E,SHULMAN G I.Cellular and molecular mechanisms of metformin action[J].Endocr Rev,2021,42(1):77-96. [7] SUN J,LIU Q,HE H,et al.Metformin treatment is associated with an increase in bone mineral density in type 2 diabetes mellitus patients in China:A retrospective single center study[J].Diabetes Metab,2022,48(5):101350. [8] MU W,LIANG G,FENG Y,et al.The potential therapeutic role of metformin in diabetic and non-diabetic bone impairment[J].Pharmaceuticals,2022,15(10):1274. [9] XIE B,CHEN S,XU Y,et al.The impact of glucagon-like peptide 1 receptor agonists on bone metabolism and its possible mechanisms in osteoporosis treatment[J].Front Pharmacol,2021(12):697442. [10] LUO G,LIU H,LU H.Glucagon-like peptide-1(GLP-1)receptor agonists:Potential to reduce fracture risk in diabetic patients?[J].Br J Clin Pharmacol,2016,81(1):78-88. [11] 韦文合,覃玉君,陈秋景,等.达格列净联合阿仑膦酸钠治疗2型糖尿病合并骨质疏松症患者的效果[J].深圳中西医结合杂志,2023,33(15):26-29. [12] SAADI M S S,DAS R,MULLATH ULLAS A,et al.Impact of different anti-hyperglycaemic treatments on bone turnover markers and bone mineral density in type 2 diabetes mellitus patients:A systematic review and meta-analysis[J]. Int J Mol Sci,2024,25(14):7988. [13] ZHANG Y S,ZHENG Y D,YUAN Y,et al.Effects of anti-diabetic drugs on fracture risk:A systematic review and network meta-analysis[J].Front Endocrinol,2021(12):735824. [14] WIKAREK A,GRABARCZYK M,KLIMEK K,et al.Effect of drugs used in pharmacotherapy of type 2 diabetes on bone density and risk of bone fractures[J].Medicina,2024,60(3):393. [15] POIANA C,CAPATINA C.Osteoporosis and fracture risk in patients with type 2 diabetes mellitus[J].Acta Endocrinol,2019,15(2):231-236. [16] ZHANG Z,CAO Y,TAO Y,et al.Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus:A meta-analysis[J].Diabetes Res Clin Pract,2020(159):107990. [17] CHEN R D,YANG C W,ZHU Q R,et al.Comparison of the effects of metformin and thiazolidinediones on bone metabolism:A systematic review and meta-analysis[J].Medicina,2023,59(5):904. [18] HIDAYAT K,DU X,WU M J,et al.The use of metformin,insulin,sulphonylureas,and thiazolidinediones and the risk of fracture:Systematic review and meta-analysis of observational studies.[J].Obes Rev,2019,20(10):1494-1503. [19] 吴晓昀,荆林林,齐夏丽.2型糖尿病患者并发骨质疏松的相关影响因素分析[J].临床医学工程,2024,31(3):379-380. [20] WANG C,XIAO F,QU X,et al.Sitagliptin,an anti-diabetic drug,suppresses estrogen deficiency-induced osteoporosisin vivo and inhibits rankl-induced osteoclast formation and bone resorption in vitro[J].Front Pharmacol,2017(8):407. [21] VIGGERS R,RASMUSSEN N H,VESTERGAARD P.Effects of incretin therapy on skeletal health in type 2 diabetes:A systematic review[J].JBMR Plus,2023,7(11):e10817. [22] CHANG C H,LU C H,CHUNG C H,et al.Dipeptidyl peptidase-4 inhibitors attenuates osteoporosis in patients with diabetes:A nationwide,retrospective,matched-cohort study in Taiwan[J].J Chin Med Assoc,2022,85(7):747-753. [23] 林赟赟,程鹏.2型糖尿病患者脆性骨折风险增加的机制[J/OL].南京医科大学学报(自然科学版),1-8[2024-08-09]. [24] KOROMANI F,GHATAN S,HOEK V M,et al.Type 2 diabetes mellitus and vertebral fracture risk[J].Curr Osteoporos Rep,2021,19(1):50-58. [25] FERRARI S L,ABRAHAMSEN B,NAPOLI N,et al.Diagnosis and management of bone fragility in diabetes:an emerging challenge[J].Osteoporos Int,2018,29(12):2585-2596. [26] EBETINO F H,SUN S,CHERIAN P,et al.Bisphosphonates:The role of chemistry in understanding their biological actions and structure-activity relationships,and new directions for their therapeutic use[J].Bone,2022(156):116289. [27] 王卢凤,张凯迪,郭艳英.抗骨质疏松药物对骨质疏松症患者糖代谢、脂代谢的影响[J].中国骨质疏松杂志,2023,29(6):886-889,896. [28] 陈胡蓉,杨宇峰,曲超,等.阿仑膦酸钠治疗糖尿病性骨质疏松症疗效及安全性Meta分析[J].辽宁中医药大学学报,2019,21(6):142-146. [29] KENDLER D L,COSMAN F,STAD R K,et al.Denosumab in the treatment of osteoporosis:10 years later:A narrative review[J].Adv Ther,2022,39(1):58-74. [30] LYU H,ZHAO S S,ZHANG L,et al.Denosumab and incidence of type 2 diabetes among adults with osteoporosis:population based cohort study[J].BMJ,2023(381):e073435. [31] 李璠,邵晋康.地舒单抗对2型糖尿病患者糖代谢及骨代谢影响的研究[J].中国骨质疏松杂志,2024,30(5):745-748. [32] XING B,YU J,ZHANG H,et al.RANKL inhibition:A new target of treating diabetes mellitus[J].Ther Adv Endocrinol Metab,2023(14):20420188231170754. [33] 邓若尘,房庆城,方睿.绝经后骨质疏松症与氧化应激的相关性研究[J].现代医院,2022,22(2):310-312,315. [34] WANG L T,CHEN L R,CHEN K H.Hormone-related and drug-induced osteoporosis:A cellular and molecular overview[J].Int J Mol Sci,2023,24(6):5814. [35] CHEN C H,CHENG T L,CHANG C F,et al.Raloxifene ameliorates glucosamine-induced insulin resistance in ovariectomized rats[J].Biomedicines,2021,9(9):1114. [36] XU B,LOVRE D,MAUVAIS-JARVIS F.The effect of selective estrogen receptor modulators on type 2 diabetes onset in women:Basic and clinical insights[J].J Diabetes Complications,2017,31(4):773-779. [37] SRINIVASAN A,WONG FK,KARPONIS D.Calcitonin:A useful old friend[J].J Musculoskelet Neuronal Interact,2020,20(4):600-609. [38] THORSØ LARSEN A,KARSDAL MA,HENRIKSEN K.Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss[J].Eur J Pharmacol,2023(954):175837. [39] HO C W,CHANG C C,WU T W,et al.Effect of Osteoporosis treatments on osteoarthritis progression in postmenopausal women:A review of the literature[J].Curr Rheumatol Rep,2024,26(5):188-195. [40] BHATNAGAR A,KEKATPURE A L.Postmenopausal osteoporosis:A literature Review[J].Cureus,2022,14(9):e29367. [41] ANASTASILAKIS A D,TSOURDI E,TABACCO G,et al.The impact of antiosteoporotic drugs on glucose metabolism and fracture risk in diabetes:Good or Bad News[J].J Clin Med,2021,10(5):996. [42] 陈睿亿,浮苗.绝经后骨质疏松症与维生素K1相关性分析[J].浙江临床医学,2024,26(2):212-214. [43] NOH J Y,YANG Y,JUNG H.Molecular mechanisms and emerging therapeutics for osteoporosis[J].Int J Mol Sci,2020,21(20):7623. [44] SKALNY A V,ASCHNER M,TSATSAKIS A,et al.Role of vitamins beyond vitamin D 3 in bone health and osteoporosis(Review)[J].Int J Mol Med,2024,53(1):9. [45] ROMANO F,SERPICO D,CANTELLI M,et al.Osteoporosis and dermatoporosis:A review on the role of vitamin D[J].Front Endocrinol(Lausanne),2023(14):1231580. [46] MACÍAS I,ALCORTA-SEVILLANO N,RODRÍGUEZ I C,et al.Osteoporosis and the potential of cell-based therapeutic strategies[J].Int J Mol Sci,2020,21(5):1653. [47] TABACCO G,BILEZIKIAN J P.Osteoanabolic and dual action drugs[J].Br J Clin Pharmacol,2019,85(6):1084-1094. [48] 黄彦钧,黄诚,沈砚主,等.罗莫佐单抗在骨质疏松症治疗中的应用[J].中华骨质疏松和骨矿盐疾病杂志,2024,17(1):81-87. [49] SAAG K G,PETERSEN J,BRANDI M L,et al.Romosozumab or alendronate for fracture prevention in women with osteoporosis.[J].N Engl J Med,2017,377(15):1417-1427. [50] STONE J A,MCCREA J B,WITTER R,et al.Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis[J].Br J Clin Pharmacol,2019,85(6):1072-1083. [51] ZAJIC S,STOCH S A,MCCREA J B,et al.A phase 1 pooled PK/PD analysis of bone resorption biomarkers for odanacatib,a Cathepsin K inhibitor[J].J Pharmacokinet Pharmacodyn,2020,47(5):473-484. [52] 阮皇菁. 骨代谢标志物检测对糖尿病性骨质疏松骨折发生的预测价值及相关性分析[J].现代诊断与治疗,2023,34(15):2223-2225. [53] XIE Y,ZINKLE A,CHEN L,et al.Fibroblast growth factor signalling in osteoarthritis and cartilage repair[J].Nat Rev Rheumatol,2020,16(10):547-564. [54] 冯璐,王瑶,张建军.LncRNA H19靶向调控miR-19b-3p/SOX9通路对脂肪间充质干细胞向成骨细胞分化的影响[J].河北医学,2024,30(7):1075-1081. [55] FU J,WANG Y,JIANG Y,et al.Systemic therapy of MSCs in bone regeneration:A systematic review and meta-analysis[J].Stem Cell Res Ther,2021,12(1):377. [56] YANG Y S,XIE J,CHAUGULE S,et al.Bone-Targeting AAV-Mediated Gene Silencing in Osteoclasts for Osteoporosis Therapy[J].Mol Ther Methods Clin Dev,2020(17):922-935. [57] 刘淏文,乔卫平,孟志成,等.骨形态发生蛋白/Wnt信号通路调控成骨:揭示骨骼形成和重塑的分子机制[J].中国组织工程研究,2025,29(3):563-571. [58] 李丽萍,李庞敏,薛升奎,等.利拉鲁肽联合唑来磷酸治疗初诊T2DM合并OP的疗效及对患者骨代谢、骨密度指标的影响[J].海南医学,2022,33(21):2730-2733. [59] 李晨. 达格列净联合地舒单抗治疗骨质疏松的临床疗效[J].中国城乡企业卫生,2024,39(6):27-30. |